Daridorexant is a prescription medication used to treat adults with chronic insomnia characterized by difficulties with sleep onset (falling asleep) and/or sleep maintenance (staying asleep). It works by blocking orexin receptors to reduce the brain’s wake drive, helping improve both total sleep time and daytime functioning. It is grouped under the following drug class(es): Hypnotics, Psychotropic agents, Schedule IV controlled substances and Sedatives. Its therapeutic use is listed as sleeping drugs. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Nemorexant and Daridorexantum. It is listed as a controlled drug substance (Schedule IV). Its PubChem CID is 91801202.
Daridorexant
| CAS No | 1505484-82-1 |
|---|---|
| Molecular Formula | C23H23ClN6O2 |
| Molecular Weight | 450.9 g/mol |
| Synonyms | [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Daridorexant is a prescription medication used to treat adults with chronic insomnia characterized by difficulties with sleep onset (falling asleep) and/or sleep maintenance (staying asleep).
The listed CAS number is 1505484-82-1.
The listed molecular formula is C23H23ClN6O2.
The listed molecular weight is 450.9 g/mol.
[(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone.
The source lists Nemorexant and Daridorexantum.